Johnson & Johnson Current Ratio 2010-2024 | JNJ
Current and historical current ratio for Johnson & Johnson (JNJ) from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Johnson & Johnson current ratio for the three months ending September 30, 2024 was 1.03.
| Johnson & Johnson Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-09-30 |
$53.25B |
$51.76B |
1.03 |
| 2024-06-30 |
$57.82B |
$53.93B |
1.07 |
| 2024-03-31 |
$57.00B |
$48.73B |
1.17 |
| 2023-12-31 |
$53.50B |
$46.28B |
1.16 |
| 2023-09-30 |
$53.70B |
$44.37B |
1.21 |
| 2023-06-30 |
$60.57B |
$54.17B |
1.12 |
| 2023-03-31 |
$64.39B |
$60.37B |
1.07 |
| 2022-12-31 |
$55.29B |
$55.80B |
0.99 |
| 2022-09-30 |
$65.24B |
$45.54B |
1.43 |
| 2022-06-30 |
$63.85B |
$44.82B |
1.42 |
| 2022-03-31 |
$60.42B |
$43.39B |
1.39 |
| 2021-12-31 |
$60.98B |
$45.23B |
1.35 |
| 2021-09-30 |
$59.89B |
$44.56B |
1.34 |
| 2021-06-30 |
$53.77B |
$38.72B |
1.39 |
| 2021-03-31 |
$52.53B |
$40.93B |
1.28 |
| 2020-12-31 |
$51.24B |
$42.49B |
1.21 |
| 2020-09-30 |
$57.58B |
$38.85B |
1.48 |
| 2020-06-30 |
$45.89B |
$36.77B |
1.25 |
| 2020-03-31 |
$44.23B |
$33.69B |
1.31 |
| 2019-12-31 |
$45.27B |
$35.96B |
1.26 |
| 2019-09-30 |
$44.33B |
$35.16B |
1.26 |
| 2019-06-30 |
$41.80B |
$31.35B |
1.33 |
| 2019-03-31 |
$41.99B |
$29.11B |
1.44 |
| 2018-12-31 |
$46.03B |
$31.23B |
1.47 |
| 2018-09-30 |
$47.19B |
$27.44B |
1.72 |
| 2018-06-30 |
$45.44B |
$27.49B |
1.65 |
| 2018-03-31 |
$42.77B |
$27.08B |
1.58 |
| 2017-12-31 |
$43.09B |
$30.54B |
1.41 |
| 2017-09-30 |
$41.83B |
$31.81B |
1.32 |
| 2017-06-30 |
$38.79B |
$28.87B |
1.34 |
| 2017-03-31 |
$63.35B |
$25.12B |
2.52 |
| 2016-12-31 |
$65.03B |
$26.29B |
2.47 |
| 2016-09-30 |
$63.32B |
$23.23B |
2.73 |
| 2016-06-30 |
$66.29B |
$21.54B |
3.08 |
| 2016-03-31 |
$62.74B |
$22.13B |
2.83 |
| 2015-12-31 |
$60.21B |
$27.75B |
2.17 |
| 2015-09-30 |
$63.49B |
$25.26B |
2.51 |
| 2015-06-30 |
$61.00B |
$24.51B |
2.49 |
| 2015-03-31 |
$58.19B |
$23.84B |
2.44 |
| 2014-12-31 |
$55.74B |
$25.03B |
2.23 |
| 2014-09-30 |
$59.97B |
$22.98B |
2.61 |
| 2014-06-30 |
$60.12B |
$24.36B |
2.47 |
| 2014-03-31 |
$57.37B |
$23.84B |
2.41 |
| 2013-12-31 |
$56.41B |
$25.68B |
2.20 |
| 2013-09-30 |
$52.18B |
$25.84B |
2.02 |
| 2013-06-30 |
$51.27B |
$23.77B |
2.16 |
| 2013-03-31 |
$47.23B |
$22.52B |
2.10 |
| 2012-12-31 |
$46.12B |
$24.26B |
1.90 |
| 2012-09-30 |
$44.79B |
$23.94B |
1.87 |
| 2012-06-30 |
$41.62B |
$23.85B |
1.75 |
| 2012-03-31 |
$57.01B |
$21.20B |
2.69 |
| 2011-12-31 |
$54.32B |
$22.81B |
2.38 |
| 2011-09-30 |
$53.44B |
$21.69B |
2.46 |
| 2011-06-30 |
$52.67B |
$20.99B |
2.51 |
| 2011-03-31 |
$49.22B |
$24.01B |
2.05 |
| 2010-12-31 |
$47.31B |
$23.07B |
2.05 |
| 2010-09-30 |
$42.72B |
$17.41B |
2.45 |
| 2010-06-30 |
$39.02B |
$17.16B |
2.27 |
| 2010-03-31 |
$38.86B |
$18.50B |
2.10 |
| 2009-12-31 |
$39.54B |
$21.73B |
1.82 |
| 2009-09-30 |
$35.60B |
$19.25B |
1.85 |
| 2009-06-30 |
$35.49B |
$19.89B |
1.79 |
| 2009-03-31 |
$34.84B |
$21.33B |
1.63 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
